NRx Pharmaceuticals (NASDAQ:NRXP) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

NRx Pharmaceuticals (NASDAQ:NRXP) released its quarterly earnings results on Friday. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10), Zacks reports.

NRx Pharmaceuticals Price Performance

NRXP opened at $2.35 on Friday. The stock has a market capitalization of $39.75 million, a PE ratio of -1.10 and a beta of 1.22. The firm’s fifty day moving average price is $3.02 and its 200 day moving average price is $2.02. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01.

Insider Transactions at NRx Pharmaceuticals

In other NRx Pharmaceuticals news, Chairman Jonathan C. Javitt purchased 40,000 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was acquired at an average cost of $1.17 per share, with a total value of $46,800.00. Following the acquisition, the chairman now owns 84,634 shares of the company’s stock, valued at approximately $99,021.78. This represents a 89.62 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 19.00% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Friday. D. Boral Capital reaffirmed a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, January 28th. Finally, Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.